STOCK TITAN

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

Overview of AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company engaged in the research and development of advanced therapeutics to address critical challenges in cancer therapy, immune-deficiency disorders, and viral diseases. With a robust focus on clinical research and strategic development, the company leverages cutting-edge biotechnology to transform the landscape of therapeutic solutions. Key industry terms such as immuno-pharma, therapeutics, and clinical trials are embedded in its research activities, underlining its commitment to modern, science-driven treatments.

Core Business Areas

AIM ImmunoTech concentrates on two major product categories. The first is an injectable formulation of naturally derived alpha interferon, designed to address specific sexually transmitted diseases, such as the treatment of certain genital warts. The second flagship therapeutic, Ampligen, is a macromolecular ribonucleic acid molecule deployed in clinical trials targeting conditions like chronic fatigue syndrome as well as multiple cancer types including renal cell carcinoma, malignant melanoma, and advanced recurrent ovarian cancer. The company’s interest in Ampligen also extends to exploring its potential as an adjuvant therapy in infectious diseases, as evidenced by its research in combination with interferon and other immune modulators.

Research, Development, and Collaborations

At the heart of AIM ImmunoTech's operations lies a rigorous commitment to clinical innovation. The company is actively involved in multi-phase clinical investigations for various conditions, including studies on refractory cancers and assessments of its drugs as vaccine adjuvants. Collaborations with esteemed institutions, such as research agreements with international partners including the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., further underscore its strategic approach to expanding the therapeutic applications of its products. These partnerships illustrate a balanced research model that addresses both immunotherapy and anti-viral research, exemplifying the company’s proficiency in navigating complex biomedical landscapes.

Operational Excellence and Strategic Positioning

AIM ImmunoTech has established itself within a competitive biopharmaceutical sector by consistently pursuing clinical research excellence and targeting unmet medical needs. Its therapeutic portfolio is designed to harness the body’s natural immune response while providing innovative clinical solutions across multiple health conditions. The company’s research efforts are supported by rigorous clinical trials and detailed investigations which focus on enhancing drug efficacy and safety. With its diversified pipeline, the company demonstrates a strategic approach to mitigating risks associated with clinical development and capitalizing on opportunities within the evolving landscape of cancer and viral treatment modalities.

Market Significance and Competitive Landscape

The company occupies a unique niche within the immuno-pharma market. Unlike larger, more diversified pharmaceutical companies, AIM ImmunoTech’s focused approach on specialized therapeutics positions it as a significant contributor to niche therapeutic areas that remain underexplored by mainstream industry players. Its collaborative research strategy and emphasis on innovative therapies such as Ampligen have helped bolster its standing within a highly competitive market. AIM’s approach combines the rigors of clinical research with strategic partnerships, ensuring that its products are developed with precision and scientific integrity.

Scientific Rigor and Clinical Expertise

Clinical investigations conducted by AIM ImmunoTech are characterized by meticulous study design and scientific scrutiny. The company has been involved in numerous phase 1, 2, and exploratory trials that seek to validate the efficacy of its compounds across various challenging conditions. By integrating detailed clinical protocols and a commitment to evidence-based research, AIM ImmunoTech showcases a depth of expertise and a nuanced understanding of the interrelationships between diverse medical conditions such as cancer, chronic fatigue syndrome, and viral infections.

Conclusion

Overall, AIM ImmunoTech Inc. stands as a model of focused innovation within the immuno-pharma sector. Its sustained commitment to advancing clinical research, developing groundbreaking therapeutics, and fostering strategic international collaborations provides a comprehensive insight into its business operations. For those seeking an in-depth understanding of a company dedicated to transforming therapeutic paradigms in oncology and virology, AIM ImmunoTech represents a case study in applied scientific expertise and clinical diligence.

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has received Ethics Committee approval in the Netherlands for its Phase 1 clinical study of Ampligen as an intranasal therapy for COVID-19 and respiratory viral diseases. The study will enroll 40 healthy subjects to evaluate safety and tolerability over 13 days. CEO Thomas K. Equels expressed optimism about the potential of Ampligen, noting previous results that showed a 90% reduction in SARS-CoV-2 infection in vitro. Enrollment is expected to start in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
-
Rhea-AI Summary

AIM ImmunoTech has received approval from the Dutch Health and Youth Care Inspectorate for a new Early Access Program to treat pancreatic cancer patients with rintatolimod (Ampligen) at Erasmus Medical Center. The initiative follows the success of a prior program, which demonstrated a significant survival benefit. Up to 16 patients will be treated, and the program aims to enhance patient selection. AIM plans to advance to clinical trials in the EU and U.S., seeking Fast Track status to expedite approval. The orphan drug designation offers ten years of market protection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.05%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech Inc. (AIM) has completed its At-The-Market (ATM) facility and closed its Equity Distribution Agreement (EDA). The company asserts it has sufficient funds to support its operational needs and clinical trials for the next 24 months. AIM plans to independently finance key developmental programs in oncology, COVID-19, ME/CFS, and Long COVID, aiming for significant advancements in 2021. CEO Thomas K. Equels highlighted the company's financial stability and commitment to achieving objectives without a renewed ATM facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
Rhea-AI Summary

AIM ImmunoTech has partnered with the Centre for Human Drug Research to conduct a clinical study on its Ampligen drug as an intranasal therapy for COVID-19. The study, titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen," will enroll 40 healthy subjects and is fully funded by AIM. Results may provide crucial insights into the potential of Ampligen as a COVID-19 treatment, though future success is uncertain and dependent on many factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the postponement of its upcoming investor conference call due to the recent passing of CEO Thomas K. Equels' mother. The company remains committed to its focus on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. The new date for the investor call will be communicated later.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

AIM ImmunoTech has initiated the dosing of its first COVID-19 'Long Hauler' patient in the AMP-511 Expanded Access Program (EAP) with Ampligen (rintatolimod). This program addresses chronic post-COVID-19 symptoms. AIM plans to host a conference call on January 12, 2021, to update on this trial and their ongoing advancements. The EAP will enroll up to 100 participants suffering from Chronic Fatigue Syndrome, including 20 Long Haulers. AIM's CEO emphasized the urgency of developing effective therapies for these long-term COVID effects, highlighting Ampligen’s potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
covid-19
-
Rhea-AI Summary

AIM ImmunoTech Inc. announced that the post-COVID-19 'Long Hauler' segment of its AMP-511 Expanded Access Program received Institutional Review Board approval for public notification of patient enrollment. The trial will include treatments with their drug Ampligen, targeting chronic fatigue symptoms in COVID-19 survivors identified as 'Long Haulers'. Up to 100 participants may be enrolled, with 20 allocated to Long Haulers. The program aims to address a significant public health need as millions face ongoing symptoms of fatigue post-COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
clinical trial covid-19
-
Rhea-AI Summary

AIM ImmunoTech has announced the approval of its post-COVID-19 Long Hauler clinical trial for its drug Ampligen. The Institutional Review Board (IRB) has authorized public notification for enrollment, allowing up to 100 participants, including 20 Long Haulers experiencing chronic fatigue post-COVID-19. Ampligen, an immune-system modulator, is already approved for Chronic Fatigue Syndrome in Argentina and is the only late-stage candidate in the U.S. for ME/CFS. AIM aims to address the critical health need for therapies targeting chronic fatigue resulting from COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
clinical trial covid-19
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) received Orphan Drug Designation from the U.S. FDA for its drug Ampligen (rintatolimod), aimed at treating pancreatic cancer. This designation grants seven years of market exclusivity upon approval. Pancreatic cancer is notably lethal, with a five-year survival rate of only 6%. Recent data from a study at Erasmus University Medical Center indicated that patients treated with Ampligen had a median survival rate 200% higher than a historical control group. However, further testing and trials are required to confirm effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.14%
Tags
none

FAQ

What is the current stock price of Aim Immunotech (AIM)?

The current stock price of Aim Immunotech (AIM) is $0.125 as of April 1, 2025.

What is the market cap of Aim Immunotech (AIM)?

The market cap of Aim Immunotech (AIM) is approximately 8.7M.

What is the core focus of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is primarily focused on the research and development of novel therapeutics to treat various forms of cancer, immune-deficiency disorders, and viral diseases.

What are the main therapeutic products developed by AIM ImmunoTech?

The company develops products such as an injectable formulation of natural alpha interferon for certain STDs and Ampligen, a macromolecular RNA-based molecule investigated for cancer, chronic fatigue syndrome, and viral infections.

How does AIM ImmunoTech position itself within the biopharmaceutical industry?

The company positions itself by focusing on specialized therapeutic areas and leveraging robust clinical research and collaborations with renowned international partners to validate its compounds.

What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?

Ampligen plays a key role as a versatile therapeutic candidate that is being evaluated for its efficacy in treating a range of conditions including various cancers, chronic fatigue syndrome, and its potential as a vaccine adjuvant.

How does the company approach clinical research and product development?

AIM ImmunoTech emphasizes rigorous clinical trial methodologies, strategic partnerships, and detailed research protocols to ensure that its therapeutic candidates meet high standards of safety and efficacy.

What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?

Its focused approach on niche therapeutic areas, commitment to innovative clinical research, and strategic international collaborations allow AIM ImmunoTech to address unmet medical needs and differentiate itself within a competitive market.
Aim Immunotech

NYSE:AIM

AIM Rankings

AIM Stock Data

8.74M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA